Structural heart disease is an important area of cardiovascular therapy as more children with congenital heart disease (CHD) are surviving into adulthood and there is an increasing prevalence of pathologies affecting heart valves and large vessels. The treatment of structural heart disease is moving from traditional open heart surgery to minimally invasive keyhole procedures. These developments need new device technologies and imaging innovations to guide them. Patients will benefit substantially from new computational tools that can simulate the effects of therapy and allow an accurate assessment of risk versus benefit.

Within King’s Health Partners there are major industrial interactions with device companies around minimally invasive interventions for repair/replacement of mitral and aortic valves and setting up and delivery of educational programs such as PCR Valve London. In addition, there are industry interactions around better treatments for patients with adult congenital heart disease undergoing catheter-based interventional treatments. Finally, there are programs around aortic disease both in better understanding and treating arterial hypertension and in technologies for improving vascular surgical procedures such as aortic dissection and aneurysms.

Some of the key aims of this theme are: